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SOCIOECONOMIC AND NUTRITIONAL PROFILE 
AND CARDIOMETABOLIC RISK FACTORS 
OF SCHIZOPHRENIC PATIENTS TREATED 
WITH ANTIPSYCHOTICS: A REFLECTION FOR 
NUTRITIONAL INTERVENTION
Perfil socioeconômico, nutricional e fatores de risco 
cardiometabólico de pacientes esquizofrênicos em uso de 
antipsicóticos: uma reflexão para intervenção nutricional
Perfil socioeconómico, nutricional y factores de riesgo 
cardiometabólico de pacientes esquizofrénicos que usan 
antipsicóticos: una reflexión para la intervención nutricional
ABSTRACT
Objective: To characterize the socioeconomic and nutritional profile and cardiometabolic 
risk factors of patients with schizophrenia treated with antipsychotics at a public hospital in 
Fortaleza, Ceará. Methods: Quantitative descriptive cross-sectional study of 146 individuals 
with schizophrenia treated with antipsychotics in a tertiary health care facility in Fortaleza, 
Ceará. Data were collected in August and September 2012. Sociodemographic interviews 
and assessment of antipsychotics, clinical examination and anthropometric measurements 
(weight, height and waist, hip and abdominal circumferences) were carried out. Results: 
Among the respondents, 44.52% (n=65) were women and 55.48% (n=81) were men. The 
majority were 20-39 years old, white (n=47; 32,19%), single (n=117; 80.14%), had 1-9 years 
of education (n=51; 34.93%), were unemployed (n=110; 75.34%) and had an income of up 
to 1 wage (n=72; 49.32%). According to BMI classification, 25.34% were overweight (n=37) 
and 28.08% (n=41) were obese. A total of 78.32% of men (n=65) and 92.06% of women 
(n=58) were at very high risk of cardiovascular disease. In all, 51.22% of men (n=42) and 
67.19% (n=43) of women were at risk of developing metabolic diseases. Conclusion: The 
study showed that most patients were in the productive period of life, were unemployed and 
had low income. It can be inferred that the majority were overweight and were more likely 
to develop metabolic disorders.
Descriptors: Schizophrenia; Antipsychotic Agents; Health Profile.
RESUMO
Objetivo: Caracterizar o perfil socioeconômico, nutricional e os fatores de risco 
cardiometabólico de pacientes com esquizofrenia em uso de antipsicóticos atendidos 
em um hospital público de Fortaleza/CE. Métodos: Estudo transversal, descritivo, 
com abordagem quantitativa, envolvendo 146 indivíduos com esquizofrenia em uso de 
antipsicóticos, acompanhados numa unidade de saúde terciária em Fortaleza/CE. A coleta 
dos dados foi realizada nos meses de agosto e setembro de 2012. Realizou-se entrevista 
contendo aspectos sociodemográficos, avaliação dos antipsicóticos, fatores de risco, exame 
clínico e medidas antropométricas (peso, altura, circunferências da cintura, do quadril e 
abdominal). Resultados: Dentre os entrevistados, 44,52% (n=65) eram mulheres e 55,48% 
(n=81) homens. A idade prevalente foi de 20 a 39 anos, 32,19% brancos (n=47), 117 
solteiros (80,14%), que tiveram de 1 a 9 anos de estudo (n=51; 34,93%), sem ocupação 
(n=110; 75,34%) e com renda de até 1 salário (n=72; 49,32%). Pela classificação do IMC, 
25,34% (n=37) apresentavam sobrepeso e 28,08% (n=41) obesidade. Dos homens, 78,32% 
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(n=65) apresentavam risco muito alto de doença cardiovascular e 
92,06% das mulheres (n=58). Da amostra, 42 homens (51,22%) e 
43 (67,19%) mulheres apresentaram risco de desenvolver doenças 
metabólicas. Conclusão: O estudo demonstrou que os pacientes 
se encontravam, em sua maior parte, na fase produtiva da vida, 
não tinham ocupação e apresentavam baixa renda. Pode-se inferir 
que a maioria estava com excesso de peso e apresentava maior 
probabilidade de desenvolver distúrbios metabólicos.
Descritores: Esquizofrenia; Antipsicóticos; Perfil de Saúde.
RESUMEN 
Objetivo: Caracterizar el perfil socioeconómico, nutricional y los 
factores de riesgo cardiometabólico de pacientes con esquizofrenia 
que usan antipsicóticos y están asistidos por un hospital público 
de Fortaleza/CE. Métodos: Estudio transversal, descriptivo 
de abordaje cuantitativo con 146 individuos con esquizofrenia 
que utilizan antipsicóticos y son asistidos por una unidad de 
salud terciaria de Fortaleza/CE. La recogida de datos se dio 
entre los meses de agosto y septiembre de 2012. Se realizó una 
entrevista sobre los aspectos sociodemográficos, la evaluación 
de los antipsicóticos, los factores de riesgo, el examen clínico 
y las medidas antropométricas (peso, altura, circunferencias 
de la cintura, del cuadril y abdominal). Resultados: De los 
entrevistados, el 44,52% eran mujeres y el 55,48% hombres. 
La franja de edad más prevalente fue entre los 20 y 39 años, el 
32,19% eran de color blanco (n=47), 117 solteros (80,14%) que 
estudiaron en un periodo entre 1 y 9 años  (n=51; 34,93%), sin 
ocupación (n=110; 75,34%) y con la renta de hasta 1 sueldo 
(n=72; 49,32%). A través de la clasificación del IMC, el 25,34% 
(n=37) presentaban sobrepeso y el 28,08% (n=41) obesidad. 
De los hombres, el 78,32% (n=65) presentaban riesgo muy 
elevado para la enfermedad cardiovascular y de las mujeres 
el 92,06% (n=58). De la muestra, 42 hombres (51,22%) y 43 
mujeres (67,19%) presentaron el riesgo de padecer enfermedades 
metabólicas. Conclusión: El estudio ha demostrado que los 
pacientes estaban, en su mayoría, en la fase productiva de la vida, 
sin ocupación y con baja renta. Se puede inferir que la mayoría 
tenía exceso de peso y presentaba más probabilidad de padecer 
disturbios metabólicos. 
Descriptores: Esquizofrenia; Antipsicóticos; Perfil de Salud.
INTRODUCTION
Schizophrenia is a severe mental disorder that affects 
about 1% of the world population(1,2). Approximately 24 
million people worldwide, mostly aged between 15 and 
35 years, live with this disease, whose prevalence occurs 
equally among men and women – although women with 
schizophrenia may have a better course of the disease than 
men(3).
Currently, the most effective treatment for patients with 
schizophrenia is the use of antipsychotics (AP). However, 
the use of these drugs – both first generation (FGAs) and 
second generation (SGAs) – involves important adverse 
effects such as weight gain, changes in lipid profile and 
glucose metabolism, resulting in increased metabolic and 
cardiovascular risk(4). This treatment may have led patients 
with chronic psychoses to be two or three times more likely 
to die from cardiovascular and metabolic diseases than the 
general population(5). Added to this, psychotic disorders 
have been associated with significant comorbidities, 
such as android obesity, type 2 diabetes, dyslipidemia, 
hypertension, metabolic syndrome, myocardial infarction 
and stroke in the long term(5,6).
Of the comorbidities listed in the literature, obesity 
stands out as a frequent event among people who use AP(4). 
Thus, risk factors such as sedentary lifestyle and unbalanced 
diet contribute to weight gain, which is linked to decreased 
basal metabolic rate, increased calorie influx and reduced 
physical activity(7).
Data from a meta-analysis(8) identified that these 
patients presented weight gain compared to those receiving 
placebo within only ten weeks of treatment. Another study(9) 
showed that the first 12 weeks of use of antipsychotic agents 
were critical for weight gain. These data demonstrate that 
this change is an early phenomenon in the pharmacological 
treatment.
The explanation for weight gain caused by 
antipsychotic drugs is not well understood; however, there 
are explanatory reports in the literature: anticholinergic and 
antihistaminergic effects, antagonism of serotonin receptors, 
and also the interference of genetic predisposition(10). The 
anticholinergic effect causes dry mouth, leading to the 
consumption of high-calorie liquids, which consequently 
increase weight. On the other hand, the antihistaminergic 
effects can lead to sedation, reducing the activities and 
movement and leading to weight gain. The 5-HT2A 
antagonism leads to increased consumption of high-calorie 
foods, which influence the body mass gain(11).  
A Brazilian study investigated metabolic changes in 
126 outpatients with schizophrenia and found a prevalence 
of approximately 80% of dyslipidemia and 40% altered 
glycemia(12). APs produce the elevation of serum lipid 
levels, especially in triglyceride levels – associated or not 
with weight gain. The mechanisms of this effect are not well 
elucidated(13). Such drugs also increase total cholesterol and 
LDL (Low Density Lipoprotein) levels and decrease HDL 
(High Density Lipoprotein) levels, which are factors that 
increase the risk of coronary heart disease(14).
62 Rev Bras Promoç Saúde, Fortaleza, 29(1): 60-67, jan./mar., 2016
Sampaio LRL, Sousa RDF, Mendonça FAC, Nascimento SS, Martins FG, Alves CRC et al.
Given the weight gain and the high risk of cardiovascular 
disease presented by patients using antipsychotics, 
it is understood that there is a need for adequate 
nutritional planning; however, it is necessary to know the 
socioeconomic and nutritional profile of this population. 
Studies on this issue enable the development of new 
proposals for intervention in order to improve the quality of 
life, provide greater longevity and support the public system 
for the provision of effective health promotion measures. 
This study aimed to characterize the sociodemographic 
and nutritional profile and cardiometabolic risk factors of 
patients with schizophrenia treated with antipsychotics at a 
public hospital in Fortaleza, Ceará. 
METHODS
This is a quantitative descriptive cross-sectional aimed 
at determining the socioeconomic and nutritional profile and 
cardiometabolic risk factors of patients with schizophrenia 
treated with antipsychotics at a tertiary health center in 
Fortaleza, Ceará. 
The research took place from August to September 
2012 at the Messejana Mental Health Hospital (Hospital 
de Saúde Mental de Messejana - HSMM) in Fortaleza, 
Ceará. Participants were selected based on the following 
criteria: individuals over 18 years old, regardless of gender, 
diagnosed with schizophrenia and treated with typical and/
or atypical antipsychotics for at least three months.
Of the 153 users found during the study period, three 
did not agree to participate and four were under 18 years 
old – therefore, they were not included. The total sample 
comprised 146 individuals attending the HSMM during 
the research period who agreed to sign the Free Informed 
Consent Form (FICF). Data were collected using a semi-
structured interview containing sociodemographic aspects, 
anthropometric measurements and waist circumference 
(WC), hip circumference (HC) and abdominal circumference 
(AC) measurements.
Body weight was measured in kilograms (kg) using 
a Filizola® digital scale with a maximum capacity of 180 
kg and 100 g graduation. The measurement was performed 
with the individual standing barefoot and wearing minimal 
clothing, with their back to the scale screen and their feet 
apart in the central region of the scale in order to keep 
the body weight evenly distributed. Height was measured 
in meters (m) by means of a stadiometer attached to the 
Filizola® digital scale with a capacity of 2 m and 0.5 m 
graduation. The measurement was performed with the 
individual in the anatomical position standing upright.
The BMI was determined by dividing the body mass 
measured in kilograms by the height in meters squared 
(BMI=weight/squared height)(15). The results were 
compared to reference values provided by the World Health 
Organization(16). Waist, hip(17) and abdominal circumference 
measurements(18) were performed using a Sanny® inelastic 
measuring tape. They are measurements that allow the 
identification of the location of body fat, since the pattern 
of fat distribution in adults is directly related to the risk 
of morbidity and mortality(15). Waist-to-hip ratio (WHR) 
was measured by dividing the waist circumference in 
centimeters (cm) by the hip circumference in centimeters, 
i.e., WHR=waist/hip. The present study adopted the 
reference values standardized by the Ministry of Health(15).
Data underwent descriptive analysis and are described 
as absolute and relative frequencies. The variables were 
grouped in tables and graphs for a better presentation of 
results and identification of relationships between them.
The study was approved by the Human Research Ethics 
Committee of the University of Fortaleza (Universidade de 
Fortaleza - UNIFOR) under Opinion No. 111.587 in order 
to meet the requirements of the National Health Council 
with regard to the guidelines and regulatory standards for 
research involving human beings(19).
RESULTS
Regarding sociodemographic data, Table I shows that 
the age between 20 and 39 years was the most prevalent 
in the study, corresponding to a percentage of 57.53% 
(n=84) of patients interviewed. As to gender, 81 (55.48%) 
of the participants were men and 65 patients (44.52%) were 
women.
In all, 73 (50.00%) participants were pardos, 117 
(80.14%) were single, 51 (34.93%) had 1 to 9 years of 
study, 36 (24.66%) were employed, and 72 had a household 
income of up to one minimum wage (49.32%).
With regard to the characterization of the nutritional 
status according to the BMI, Table II shows that 41 (28.08%) 
patients were at normal weight, 41 presented grade I obesity 
(28.08%) and 37 (25.34%) were overweight.
Based on the WHR, which assesses the risk of 
cardiovascular diseases, it was observed that the majority 
of men – 65 (78.32%) – presented very high risk of 
cardiovascular disease (Table III), and so did women – 58 
(92.06%).
Data on the abdominal circumference shows that 
most men and women – 42 (51.22%) and 43 (67.19%), 
respectively – are at “very high risk of metabolic diseases” 
(Table IV).
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Table I - Distribution of patients with schizophrenia in the Messejana Mental Health Hospital (Hospital de Saúde Mental de 
Messejana - HSMM) treated with antipsychotics regarding their sociodemographic profile. Fortaleza, Ceará, 2012.
Characteristics n     Percentage (%)
Age (years)
18-19 years                        08   5.48
20-39 years                     84 57.53
40-59 years           44 30.14
60 years and older                 10   6.85
Gender
Men 81 55.48
Women 65 44.52
Race
White 47 32.19
Black 07   4.79
Mixed-race 11   7.53
Mulatto 08   5.48
Pardo 73 50.00
Marital Status
Single/ 117 80.14
Married 16 10.96
Common-law marriage 08   5.48
Widowed 05   3.42
Education (years of study)
0 years 29 19.86
1-9 years 51 34.93
10-12 years 29 19.86
13 years or more 37 25.34
Profession/occupation
Yes 36 24.66
No 110 75.34
Monthly Household Income in MW
Up to 1 wage 72 49.32
1-2 wages 57 39.04
3-6 wages 16 10.96
7-10 wages 01   0.68
MW: current minimum wage R$ 622.00. 
Table II - Distribution of patients with schizophrenia in the Messejana Mental Health Hospital (Hospital de Saúde Mental de 
Messejana - HSMM) treated with antipsychotics regarding their body mass index. Fortaleza, Ceará, 2012. 
Characteristics n Percentage (%)
Mild Thinness                     2   1.37
Normal                    41 28.08
Overweight         37 25.34
Obesity Class I                41 28.08
Obesity Class II 21 14.38
Obesity Class III 4    2.75
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DISCUSSION 
In the present study, most respondents were in the 
age group 20-39 years. Similar results were found in other 
studies involving patients with schizophrenia(16,20) and an 
older age group – 22 to 50 years (47.3%) – was found in 
another scientific research(21).
The analysis of the distribution of gender among 
patients revealed a similarity between the frequencies of 
male and female subjects. The same results were found 
in other studies(22,23) that reported a similar distribution of 
the overall prevalence of schizophrenia among men and 
women.
There was a higher number of pardos and single 
individuals in the findings of the present study, a result that 
is consistent with a descriptive analysis(22) conducted in 
Feira de Santana, Bahia, which confirms the results reported 
by our study regarding these aspects.
Most participants in the present study had 1 to 9 years 
of study, were unemployed and had a household income 
of up to 1 minimum wage. A study conducted with 178 
patients with schizophrenia found similar results – the 
majority of respondents (69.2%) did not complete primary 
school, 20% were illiterate and 96.3% were unemployed(24). 
However, in another study(25), a slightly lower percentage – 
58.8% – of patients were unemployed and had an income 
of up to 1 minimum wage. These data are in line with the 
sociodemographic indicators of the Brazilian population – 
the average education of Brazilian individuals for the year 
2012 was 8.8 years of study(26); however, such similarity was 
not observed in income – the monthly household income of 
the Brazilian individuals is a little more than two minimum 
wages(27) and the household income of the study sample was 
of up to one minimum wage.
Given the above, it is clear the precariousness 
of sociodemographic conditions of individuals living 
with schizophrenia, which appears as a barrier to the 
implementation of educational activities for the patient and 
family as an essential support to changes in lifestyle in these 
people, who are vulnerable to metabolic and cardiovascular 
diseases. These patients have a mortality rate that is two 
times higher than that of the general population given the 
higher prevalence and severity of clinical conditions and 
the life expectancy 20% lower compared to the average of 
people who do not have the disease(28).
The assessment of the nutritional status of patients 
treated with antipsychotics revealed that most patients were 
overweight or presented some degree of obesity, suggesting 
a higher risk of metabolic disorders. It was found, in the 
study sample, a very high risk of cardiovascular disease 
when assessing WHR and very high risk of metabolic 
disorders when assessing the AC. In addition to weight 
gain, a similar study highlights glucose intolerance, diabetes 
mellitus, hypertension, and lipid disorders as changes found 
in these individuals(29).
A cohort study conducted in the UK with 46,000 people 
with severe mental illness, particularly schizophrenia, 
and 300,000 controls revealed rates of risk of death from 
Table III - Distribution of patients with schizophrenia in the Messejana Mental Health Hospital (Hospital de Saúde Mental 
de Messejana - HSMM) treated with antipsychotics regarding waist-to-hip ratio. Fortaleza, Ceará, 2012.
Characteristics
WHR
Men Women
n Percentage (%) n Percentage (%)
Moderate                      3   3.61 0 0.00
High risk                15 18.07 5 7.94
Very high risk 65 78.32 58 92.06
WHR: Waist-to-hip Ratio.
Table IV - Distribution of patients with schizophrenia in the Messejana Mental Health Hospital (Hospital de Saúde Mental 
de Messejana - HSMM) treated with antipsychotics regarding abdominal circumference values. Fortaleza, Ceará, 2012.
Characteristics
CA
Men Women
n Percentage (%) n Percentage (%)
Normal                      16 19.51 12 18.75
Moderate risk 2   2.44 3   4.69
High risk          22 26.83 6   9.37
Very high risk 42 51.22 43 67.19
AC: Abdominal circumference.
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cardiovascular disease (CVD) three times higher in the 
age group 18-49 years and two times higher in the age 
group 50-75 years(22). In a recent national prospective study 
conducted in Sweden with 8,300 people with schizophrenia, 
the rates of risk of death from CVD was 3.3 among women 
(decreased life expectancy by 12 years) and 2.2 among men 
(decreased life expectancy by 15 years)(21); additionally, the 
increase in the rates of death from CVD associated with 
schizophrenic has been confirmed in autopsy studies(24).
There is contemporary evidence of an increase in 
mortality rate in schizophrenia, and this increase is in large 
part related to CVD. The exact origin of vulnerability to 
this clinical situation in schizophrenia remains unclear 
and probably cannot be attributed to a single mechanism. 
The interpretation of the findings shows that there are little 
studied issues such as the assessment of naive patients 
treated with antipsychotics and those with a long term use. 
Therefore, it is a problem that should be more investigated 
given its multifactorial causality(30).
Overweight and obesity are common comorbidities 
among patients with schizophrenia treated with AP; in 
addition, these patients have presented a higher BMI 
compared to psychiatric patients who are not treated with 
antipsychotics and the general population(4,31,32).
In Brazil, data from Ministry of Health show a 
prevalence of 32% for overweight and 8% for obesity(33). 
On the other hand, the reported prevalence of obesity in the 
population of patients with schizophrenia treated with drugs 
ranges between 40% and 60%(34). These indicators reveal a 
close scientific relationship between the present study and 
the results already presented by researchers in this area. 
This draws attention to a multidisciplinary approach and 
non-pharmacological interventions as an alternative(35).
In addition to the excessive weight observed, another 
parameter that was altered was the AC, which was increased 
in 80% of women and 81% of men in our sample. Such 
finding was similar to that of another study, which found 
that AC was increased in 50% of the sample, reinforcing 
the theory that denotes the prevalence and the associated 
deleterious effects(36). However, these values were superior 
to that found in another study(32) that assessed 80 patients 
with schizoaffective disorder. 
The sedentary lifestyle may be justified by the 
unemployment, low income and other unfavorable 
sociodemographic conditions that have been found in our 
study and also the treatment with AP, which can lead to or 
aggravate metabolic disorders(37-41).
Thus, it is important that non-pharmacological measures 
are implemented in order to reduce its negative effects(7). 
Therefore, it is necessary to develop a weight gain prevention 
program based on the specificities of patients, adapting 
physical activity and nutrition guidance to the limitations 
imposed by the disease(7). In this line of thought, it is worth 
noting that physical activity as an interventionist measure 
should be aimed at social integration and improvement of 
physical performance as a routine strategy(42).
A literature review(41) shows that these patients are 
more likely to develop metabolic syndrome because the use 
of AP, in addition to causing weight gain, can trigger lipid 
abnormalities such as elevated levels of LDL cholesterol 
and triglycerides(28). This is because the chronic treatment, 
especially with atypical AP, promotes the antagonism of 
5-HT2C receptor (5-HT2cR), and this can contribute to the 
development of metabolic syndrome(37).
Thus, assuming that there is a risk of cardiovascular 
disease and metabolic syndrome induced by AP, this 
research points to the need for actions aimed at the factors 
– whether biomedical or sociodemographic – that lead to 
the onset of these disorders. Thus, simple attitudes, such 
as measuring patients’ weight, asking them to write a food 
diary, encouraging them to do regular physical activity 
and referring them to a nutritionist, appear as promising 
interventions(28).
CONCLUSION
The study showed that most patients were in the 
productive stage of life, were unemployed and had low 
income. It can be inferred that most of them were overweight 
and more likely to develop metabolic disorders.
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